Profile data is unavailable for this security.
About the company
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
- Revenue in JPY (TTM)1.04tn
- Net income in JPY326.37bn
- Incorporated1943
- Employees7.60k
- LocationChugai Pharmaceutical Co Ltd15F, Nihonbashi Mitsui Tower2-1-1, Nihonbashi-Muro-machiCHUO-KU 103-8324JapanJPN
- Phone+81 332816611
- Fax+81 332812828
- Websitehttps://www.chugai-pharm.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 505.36bn | 96.03bn | 5.83tn | 19.61k | 60.54 | 6.40 | -- | 11.53 | 0.6963 | 0.6963 | 3.66 | 6.59 | 0.5263 | 1.59 | 4.43 | 1,189,383.00 | 9.96 | 13.68 | 10.86 | 15.20 | 83.56 | 85.87 | 18.91 | 20.01 | 8.50 | -- | 0.0066 | 23.77 | 7.26 | 5.55 | 10.14 | 1.14 | 22.90 | 9.45 |
| Haleon PLC | 2.29tn | 220.40bn | 6.32tn | 24.00k | 29.11 | -- | 165.21 | 2.76 | 0.1168 | 0.1168 | 1.21 | -- | -- | -- | -- | 468,125.00 | -- | -- | -- | -- | 61.71 | -- | 10.12 | -- | -- | 7.27 | -- | -- | 4.09 | -- | -1.04 | -- | -- | -- |
| Takeda Pharmaceutical Co Ltd | 4.26tn | 144.07bn | 6.82tn | 49.28k | 46.98 | 0.9244 | 7.82 | 1.60 | 91.21 | 91.21 | 2,714.06 | 4,635.56 | 0.2934 | 1.30 | 7.18 | 86,519,390.00 | 0.9922 | 1.65 | 1.19 | 1.97 | 66.54 | 68.05 | 3.38 | 6.06 | 0.5831 | 2.40 | 0.3997 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
| Sun Pharmaceutical Industries Ltd | 912.29bn | 180.14bn | 7.20tn | 43.00k | 39.94 | 6.01 | 31.34 | 7.89 | 39.92 | 39.92 | 202.11 | 265.35 | 0.5836 | 1.02 | 4.27 | 11,278,340.00 | 11.61 | 7.77 | 15.75 | 10.85 | 78.01 | 71.59 | 19.89 | 14.23 | 1.98 | 104.93 | 0.0465 | 38.64 | 10.51 | 10.78 | 13.01 | 29.15 | -7.28 | 37.47 |
| Chugai Pharmaceutical Co Ltd | 1.04tn | 326.37bn | 10.05tn | 7.60k | 30.17 | 6.00 | -- | 9.70 | 198.34 | 198.34 | 629.63 | 997.97 | 0.5647 | 1.21 | 3.45 | 136,254,000.00 | 17.79 | 19.29 | 20.95 | 23.91 | 67.67 | 63.57 | 31.50 | 28.39 | 4.37 | -- | 0.00 | 40.14 | -11.78 | 13.90 | -13.08 | 28.61 | -0.8947 | 27.23 |
| Merck KGaA | 3.57tn | 466.59bn | 11.36tn | 62.35k | 24.35 | 2.37 | 14.66 | 3.19 | 6.27 | 6.27 | 47.90 | 64.39 | 0.4243 | 1.82 | 4.81 | 330,959.50 | 5.57 | 5.64 | 6.96 | 7.27 | 58.03 | 61.86 | 13.13 | 12.97 | 0.8157 | 29.56 | 0.261 | 9.26 | -5.57 | 7.19 | -15.09 | 21.40 | 14.77 | 11.97 |
| Daiichi Sankyo Co Ltd | 1.60tn | 200.73bn | 11.58tn | 18.73k | 56.86 | 6.76 | 44.44 | 7.23 | 104.62 | 104.62 | 834.79 | 880.40 | 0.5366 | 1.12 | 3.99 | 85,532,790.00 | 6.73 | 4.99 | 8.53 | 6.14 | 74.07 | 69.10 | 12.55 | 9.94 | 2.40 | -- | 0.0846 | 51.87 | 25.28 | 11.49 | 85.90 | 16.67 | 13.01 | 16.47 |
| GSK plc | 6.26tn | 912.55bn | 12.91tn | 70.21k | 14.01 | 4.58 | 9.11 | 2.06 | 1.09 | 1.09 | 7.48 | 3.34 | 0.525 | 1.51 | 4.50 | 437,816.90 | 8.13 | 6.74 | 12.25 | 10.71 | 72.76 | 70.29 | 15.48 | 16.93 | 0.5796 | 11.37 | 0.5733 | 79.55 | 3.42 | -0.322 | 15.79 | 7.10 | 5.47 | -10.32 |
| Zoetis Inc | 1.38tn | 376.59bn | 13.08tn | 14.10k | 35.09 | 16.45 | 28.79 | 9.51 | 5.19 | 5.19 | 18.95 | 11.07 | 0.6216 | 1.00 | 7.05 | 619,432.60 | 17.00 | 14.47 | 19.66 | 17.18 | 70.11 | 69.77 | 27.34 | 25.77 | 1.94 | 16.81 | 0.5659 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Bristol-Myers Squibb Co | 7.17tn | -968.34bn | 13.78tn | 34.10k | -- | 5.30 | 23.46 | 1.92 | -3.10 | -3.10 | 22.15 | 8.14 | 0.4711 | 3.92 | 5.18 | 1,335,308.00 | -6.35 | 3.05 | -8.27 | 3.76 | 75.94 | 76.13 | -13.47 | 7.69 | 0.9947 | 15.53 | 0.7709 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 31 May 2024 | 49.93m | 2.97% |
| Nikko Asset Management Co., Ltd.as of 05 Jul 2024 | 24.27m | 1.45% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 23.28m | 1.39% |
| Daiwa Asset Management Co. Ltd.as of 28 Jun 2024 | 22.55m | 1.34% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 18.85m | 1.12% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 14.92m | 0.89% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 2024 | 12.48m | 0.74% |
| Harding Loevner LPas of 30 Apr 2024 | 11.94m | 0.71% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 9.70m | 0.58% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 05 Jul 2024 | 6.18m | 0.37% |
